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Introduction
Over the past several years, significant advances have
been made in understanding the pathophysiology of RA in
the joint. The earlier diagnosis of RA combined with an
early initiation of an appropriate treatment regimen are
acknowledged as important factors for improved clinical
outcomes. Furthermore, the introduction of new, targeted
therapies has significantly advanced the treatment of and
quality of life of patients with RA [1,2]. The rationale for
early diagnosis and availability of targeted aggressive
therapy has fueled the need for powerful, sensitive imaging
techniques that can be used not only to accurately diag-
nose and indicate the prognosis of patients with RA, but
also to monitor the efficacy of long-term treatment.
Radiographs, although able to detect structural joint
damage in patients with established disease, have not
been sensitive in detecting early RA disease pathology in
the patient [3]. There has therefore been an increasing
interest in magnetic resonance imaging (MRI), with the aim
of providing more sensitive data and better predictive value
[3]. This review will evaluate the use of MRI as a tool for the
diagnosis, classification, and clinical monitoring of RA.
Potential of MRI
The ability of MRI to assess both detailed changes in bone
structure (i.e. erosions) and synovial inflammation com-
bined with its multiplanar capability makes it a potentially
valuable tool for assessing patients with RA. Such capabil-
ities mean that MRI can be used in a variety of ways, as
summarized in Table 1.
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Abstract
Early diagnosis of rheumatoid arthritis (RA) combined with early initiation of an appropriate treatment
regimen is acknowledged as an important factor in improving clinical outcomes in patients with RA. Early
diagnosis allows treatment intervention to occur sooner in order to inhibit the progression of structural
joint damage as well as providing improved patient quality of life. Unfortunately, early diagnosis has been
challenging due to the non-specific signs and symptoms associated with many polyarthropathies and
the lack of accurate definitive diagnostic tests that can accurately classify RA at presentation. The
emphasis on early diagnosis has fueled the need for powerful, sensitive, non-invasive imaging
techniques that not only accurately define RA and give an indication of prognosis, but can also serve as
a tool to monitor long-term treatment outcomes. This article reviews the potential uses of magnetic
resonance imaging as a tool for the classification, documentation, and clinical monitoring of RA.
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Early diagnosis of RA
RA is a progressive disease that, if left unchecked, results
in irreversible joint damage. Early diagnosis is often difficult
due to the non-specific symptoms and signs that develop
relatively slowly. In particular, the conventional diagnostic
criteria developed by the American College of Rheumatol-
ogy (ACR) among patients, the slow development of signs
and symptoms, and ambiguous symptoms similar to other
inflammatory polyarthropathies. Furthermore, conventional
diagnostic criteria developed by the ACR were derived
from patients with established disease [4]. These criteria
were not designed to detect early clinical symptoms of the
disease process. In fact, recent data suggest that, in the
first 3 months during disease onset, ACR criteria may well
be misleading rather than helpful in making a definitive
diagnosis of RA [5]. The natural history of RA is such that
the early months of disease are a critical period during
which irreversible joint damage occurs. The advantages of
an accurate, early clinical RA diagnosis thus emphasize the
need for more accurate methods of detection [6]. It should
be noted, however, that currently the majority of patients do
not present with a disease duration of less than 3 months,
therefore ACR criteria would be valid. However, as indi-
cated later, the majority of joint erosions are not detected
by radiographic analysis in patients at presentation.
The current ACR recommendations for diagnosing RA
include radiographic analysis of selected joints. The sensi-
tivity of radiography, however, is very limited. For instance,
at presentation, the characteristic or pathognomonic
radiographic-identified joint erosion was detected in only
15% of patients with RA [7]. In contrast, when imaged by
MRI, abnormalities were detected in 70% of patients,
involving 35% of the patients’ joints. In another study, MRI
was performed on 42 patients with early RA (median
disease duration, 4 months) at baseline and at 1 year. Syn-
ovitis, measured by MRI, was predictive for the develop-
ment of joint erosions at 1 year [8]. The use of imaging has
allowed the distinction to be made between entheseal-
based disease and primary intrasynovial disease [9]. For
example, MRI has been shown to be useful in differentiat-
ing polymyalgia rheumatica from RA by imaging extracap-
sular enhancement in the latter [10,11]. MRI has been
used to determine whether recent-onset knee synovitis dif-
fered in RA patients compared with those who had
spondyloarthropathy. Data showed that the non-RA
patients had a periarticular location of entheseal inflamma-
tion and bone edema, while RA patients did not [12]. In
another study, RA patients classified with a good progno-
sis (defined as acute onset [~24 hours] of disease) were
shown to have the same characteristic entheseal pathol-
ogy as opposed to the intrasynovial inflammatory pathol-
ogy of RA and, importantly, MRI detection of enthesitis
correlated closely with favorable clinical outcomes (not
requiring disease-modifying therapy) in these patients [4].
The characteristic feature of the good-prognosis patients
(all of whom fulfilled the ACR diagnostic criteria for RA)
was that they lacked the intra-articular ‘bare area’ region
lesions, whereas such a change was a universal feature of
poor prognosis in other RA patients studied. This finding
suggests that many RA patients with a good prognosis
exhibit a unique pathology, an important clinical considera-
tion. Unfortunately, these differences between diseases
have been difficult to detect during routine clinical exami-
nation, providing further rationale for the use of MRI as a
diagnostic tool in this subset of patients.
Validation and imaging of MRI
Validation of MRI as a tool in RA has been undertaken in a
variety of ways. These include evaluating biopsies of MRI
bone erosions (obtained under ultrasound guidance), cor-
relating the MRI bone erosions with ultrasound erosions
(and radiographs), and conducting longitudinal studies to
assess the long-term outcome of MRI studies.
Ultrasound and MRI modalities measure different physical
characteristics of erosions, with ultrasound identifying the
absence of a cortical echo and MRI detecting change in
nuclear spin in response to a magnetic field. When MRI
lesions are compared with ultrasound erosions, the two
modalities act as a cross-reference for each other [13].
Studies undertaking these comparisons have shown that
the cortical defects observed from ultrasound are closely
correlated with MRI abnormalities on T1-weighted images
[6] with all MRI lesions correlating with a cortical defect
on ultrasound.
Table 1
Potential uses for magnetic resonance imaging in rheumatoid arthritis (RA)
Accurate diagnosis and classification of patients with RA at presentation
Early assessment of bony erosions to define patients who already have articular structural damage
Quantification of synovial inflammation at the primary site, potentially allowing prediction of further erosions and disease progression
Simultaneous assessment of synovitis and joint erosion pathologies, allowing for dissection of the relative importance of these two pathologies in 
RA disease progression
Long-term evaluation of treatment outcome in clinical trials and real-world settingsS8
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In one study, the presence of a MRI lesion was confirmed
on ultrasound and then, under ultrasound guidance, tissue
was obtained from the confirmed MRI erosion site [14].
Five patient biopsies were obtained, all of which contained
bone, and three of which were also associated with cellu-
lar material. Furthermore, one patient biopsy had a distinct
population of CD34+ cells. The close correlation between
ultrasound and MRI-detected bone erosions thus strongly
supports the conclusion that MRI is measuring genuine
abnormalities.
The sensitivity of MRI for detecting bone erosions has also
been compared with radiography. In one comparison
study, radiographic analysis detected bone erosions in
15% of RA patients (median symptom duration,
4 months), whereas MRI analysis detected erosions in
45% of RA patients [7]. Furthermore, longitudinal studies
confirmed that lesions seen with MRI appear later as
radiographic erosions. RA patient follow-up over 5 years
showed that, at baseline, only 20% of MRI lesions were
detected by radiographic analysis, while at 5 years 60% of
MRI lesions were detected by radiographic analysis [9].
This reflects both the lack of sensitivity of radiography and
the delay in the visualization of lesions using this tech-
nique. One potential explanation for this discrepancy may
be that, at presentation, the majority of lesions detected
are small in size; later, as the disease progresses, the
lesions increase in size. Unfortunately, of all the bone ero-
sions detected by radiography, only approximately 10% of
these identified lesions were classified as small in size
[6,9]. Thus, in addition to lacking the capacity for multi-
planar imaging, radiographs do not detect early bone ero-
sions because early RA is characterized by small erosions,
which are below the threshold of radiographic detection.
Synovitis and intra-relationship with bony
damage
The intra-relationship between synovitis and bony damage
has also been addressed using patients with very early
disease onset. The importance of studying this particular
patient group is the lack of confounding influences of pre-
vious treatments, such as disease-modifying antirheumatic
drugs (e.g. methotrexate). In a recent study, patients were
randomized to receive treatments that had different time-
frames for onset of action [11]. Bone damage and synovi-
tis were measured by MRI. The MRI data suggested that
the level of synovial thickness was critical in determining
the amount of bone damage. In fact, the area under the
curve for synovial thickness was the sole predictor of sub-
sequent bony damage. Importantly, no damage occurred
in joints without synovitis; thus, the presence of synovitis
was prognostic for bone damage.
Synovitis is the primary abnormality in RA, and MRI, unlike
radiology, can be used to image the synovium. Both the
synovial volume and the level of inflammation can be inde-
pendently assessed using MRI. The most common and
extensively studied MRI method is the use of the magnetic
contrast medium, gadolinium-diethylenetriamine penta-
acetic acid. Early studies correlated the gadolinium-
enhancing imaging properties in the synovium with the
microscopic appearances on arthroscopic biopsies
[15,16]. In one study, it was clearly demonstrated that the
correlations between inflammation and histology held true
for the site of biopsy, but the correlation diminished when
random sites were assessed [16]. Other studies have
evaluated dynamic imaging using multiple slices across
the joint and have shown the ability of this technique to
distinguish between two active therapies [17].
Although clinical examination has been a cornerstone in
identifying and monitoring disease progression in RA
patients, MRI has been shown to be more sensitive than
clinical examination for identifying synovitis. Studies from a
Japanese group correctly diagnosed 25 out of 26 patients
at RA disease onset using MRI criteria, which was 23%
more patients than were identified using ACR criteria [18].
In a recent study comparing MRI, ultrasound, and clinical
examination, results again confirmed the sensitivity of MRI in
RA. These data suggest that, as MRI becomes more wide-
spread, it will serve as a more accurate measure for identify-
ing key pathologic features of RA that are not readily
identified using standard ACR criteria, such as synovitis.
Predicting disease progression and
monitoring treatment outcome
A key issue in RA patient management is whether MRI
imaging of RA patients at disease onset can accurately
predict the rate of disease progression. This issue is
further complicated by the fact that the natural history of
the disease is now rarely observed and because treatment
is being administered earlier in the disease process.
Despite the complexities inherent in predicting disease
progression, some generalizations can be made. While
the T1-weighted lesions (the anatomical cortical lesions
conventionally called bony erosions) correlate best, the
T2-suppressed lesions represent bony edema and a
response to bone inflammation. It would be reasonable to
predict that these latter lesions are the ones that will
progress. However, unequivocal evidence is lacking, in
part due to the institution of aggressive treatment in RA
patients. Nevertheless, there is sufficient evidence to
suggest that untreated patients with characteristic disease
at onset with T1-weighted lesions surrounded by edema
on T2-fat suppressed images are likely to progress. There-
fore, MRI is valuable in predicting disease progression at
least in a subset of RA patients.
MRI has the ability to assess bone damage, which has
been crucial in allowing increased sensitivity for assessing
therapeutic regimens. It is unlikely in the near future that
MRI will replace radiographic analysis in establishedS9
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disease, since radiographs are a better tool for imaging
multiple affected joints. However, the ability to measure
synovial volume may be more important over the long term
to assess the efficacy of new or modified therapies
designed to significantly decrease the rate of radiologic
structural damage. If rheumatologists concur that synovitis
is the primary abnormality in RA, then the accurate assess-
ment of synovial volumes may replace structural damage
as the most pertinent long-term clinical endpoint.
MRI may also be beneficial in functional status assess-
ment for patients in which joint erosions have been mini-
mized due to advances in early diagnosis and treatment
modalities. For example, MRI has been shown to be a sen-
sitive tool for the detection of inflammation of periarticular
tendons and tendon sheaths [19]. Although MRI tendon
imaging would not add to the assessment of structural
damage, as rheumatologists are able to minimize joint
erosion, damage to tendons may contribute significantly to
functional status. MRI could a play a key role in detecting
and measuring decreased functional status due to ten-
donitis or tendon rupture and MRI would provide greater
accuracy than physical examination.
Limitations of MRI
A major concern with the use of MRI in RA has been the
validation of bone erosion scoring. The European League
Against Rheumatism and the Outcome Measures in
Rheumatoid Arthritis Clinical Trial working groups have
both undertaken cross-sectional (and the former group
also longitudinal) analyses of RA bone erosion scoring
using MRI [20,21]. When the strict criteria for the defini-
tion of bone erosions (lesion observed in two imaging
planes involving a cortical break in at least one) are
applied to scoring, there is a 97% consistency in the
recording of such lesions by MRI [20].
Summary
MRI is a sensitive, accurate, non-invasive tool that allows
simultaneous assessment of all the components of
diarthrodial joints. MRI-imaged abnormalities can be iden-
tified in the majority of RA patients at disease presenta-
tion. Furthermore, MRI provides the unique opportunity to
assess RA disease progression since new efficacious
agents such as infliximab (cA2, Remicade®; Centocor,
Inc., Malvern, PA, USA) and etanercept (Enbrel®; Immunex
Corporation, Seattle, WA, USA) have been shown to
inhibit the progression of structural damage. Preventing
progression of structural damage will limit the utility and
need for long-term patient monitoring by radiographic
analysis as RA patients are diagnosed early and treated
aggressively. In conclusion, the implementation of MRI will
provide clinicians with a powerful imaging tool for long-
term, periodic monitoring of the RA disease state.
References
1.  Feldmann M, Maini RN: Anti-TNFα α therapy of rheumatoid arthritis:
what have we learned? Annu Rev Immunol 2001, 19:163-196.
2. O’Dell  JR:  How is it best to treat early rheumatoid arthritis
patients? Baillieres Best Pract Res Clin Rheumatol 2001, 15:
125-137.
3.  McGonagle D, Conaghan PG, Wakefield R, Emery P: Imaging
the joints in early rheumatoid arthritis. Bailleres Best Pract Res
Clin Rheumatol 2001, 15:91-104.
4.  McGonagle D, Gibbon W, O’Connor P, Green M, Pease C,
Ridgway J, Emery P: An anatomical explanation for good-prog-
nosis rheumatoid arthritis. Lancet 1999, 353:123-124.
5.  Green M, Marzo-Ortega H, McGonagle D, Wakefield R, Proud-
man S, Conaghan P, Gooi J, Emery P: Persistence of mild, early
inflammatory arthritis: the importance of disease duration,
rheumatoid factor, and the shared epitope. Arthritis Rheum
1999, 42:2184-2188.
6.  Wakefield RJ, Gibbon WW, Conaghan PG, O’Connor P,
McGonagle D, Pease C, Green MJ, Veale DJ, Isaacs JD, Emery P:
The value of sonography in the detection of bone erosions in
patients with rheumatoid arthritis: a comparison with conven-
tional radiography. Arthritis Rheum 2000, 43:2762-2770.
7.  McQueen FM, Stewart N, Crabbe J, Robinson E, Yoeman S, Tan
PL, McLean L: Magnetic resonance imaging of the wrist in
early rheumatoid arthritis reveals a high prevelance of ero-
sions at four months after symptom onset. Ann Rheum Dis
1998, 57:350-356.
8.  Huang J, Stewart N, Crabbe J, Robinson E, McLean L, Yeoman S,
Tan PL, McQueen FM: A 1-year follow-up study of dynamic
magnetic resonance imaging in early rheumatoid arthritis
reveals synovitis to be increased in shared epitope-positive
patients and predictive of erosions at 1 year. Rheumatology
(Oxford) 2000, 39:407-416.
9.  Albers JMC, Paimela L, Kurki P, Eberhardt KB, Emery P, van’t Hof
MA, Schreuder FH, Leirisalo-Repo M, van Riel PL: Treatment
strategy, disease activity, and outcome in four cohorts of
patients with early rheumatoid arthritis. Ann Rheum Dis 2001,
60:453-458.
10.  McGonagle D, Pease C, Marzo-Ortega H, O’Connor P, Gibbon
W, Emery P: Comparison of extracapsular changes by mag-
netic resonance imaging in patients with rheumatoid arthritis
and polymyalgia rheumatica. J Rheumatol 2001,  28:1837-
1841.
11.  Ostergaard M, Hansen M, Stoltenberg M, Gideon P, Klarlund M,
Jensen KE, Lorenzen I: Magnetic resonance imaging-deter-
mined synovial membrane volume as a market of disease
activity and a predictor of progressive joint destruction in the
wrists of patients with rheumatoid arthritis. Arthritis Rheum
1999, 42:918-929.
12.  Gaffney K, Cookson J, Blake D, Coumbe A, Blades S: Quantifica-
tion of rheumatoid synovitis by magnetic resonance imaging.
Arthritis Rheum 1995, 38:1610-1617.
13.  Tamai K, Yamato M, Yamaguchi T, Ohno W: Dynamic magnetic
resonance imaging for the evaluation of synovitis in patients
with rheumatoid arthritis. Arthritis Rheum 1994, 37:1151-1157.
14.  McGonagle D, Gibbon W, O’Connor P, Blythe D, Wakefield R,
Green M, Veale D, Emery P: A preliminary study of ultrasound
aspiration of bone erosion in early rheumatoid arthritis.
Rheumatology (Oxford) 1999, 38:329-331.
15. Ostergaard M, Stoltenberg M, Lovgreen-Neilsen P, Volck B,
Jensen CH, Lorenzen I: Magnetic resonance imaging-deter-
mined synovial membrane and joint effusion volumes in
rheumatoid arthritis and osteoarthritis: comparison with the
macroscopic and microscopic appearance of the synovium.
Arthritis Rheum 1997, 40:1856-1867.
16.  Veale DJ, Reece RJ, Parsons W, Radjenovic A, O’Connor PJ,
Orgles CS, Berry E, Ridgway JP, Mason U, Boylston AW, Gibbon
W, Emery P: Intra-articular primatised anti-CD4: efficacy in
resistant rheumatoid knees. A study of combined
arthroscopy, magnetic resonance imaging, and histology. Ann
Rheum Dis 1999, 58:342-349.
17.  Reece RJ, Canete JD, Parsons WJ, Emery P, Veale DJ: Distinct
vascular patterns of early synovitis in psoriatic, reactive, and
rheumatoid arthritis. Arthritis Rheum 1999, 42:1481-1484.
18. Sugimoto H, Takeda A, Kyodoh K: Early-stage rheumatoid
arthritis: prospective study of the effectiveness of MR imaging
for diagnosis. Radiology 2000, 216:569-575.S10
Arthritis Research    Vol 4 Suppl 2 Emery
19.  Kainberger F, Trattnig S, Czerny C, Seidl G, Kritz H, Imhof H: MRI
in assessment of the systemic manifestations of rheumato-
logical disease. Br J Rheumatol 1996, 35(suppl 3):40-44.
20.  Ostergaard M, Klarlund M, Lassere M, Conaghan P, Peterfy C,
McQueen F, O’Connor P, Schnier R, Stewart N, McGonagle D,
Emery P, Genant H, Edmonds J: Interreader agreement in the
assessment of magnetic resonance images of rheumatoid
arthritis wrist and finger joints—an international multicenter
study. J Rheumatol 2001, 28:1143-1150.
21.  Conaghan P, Edmonds J, Emery P, Genant H, Gibbon W, Klar-
lund M, Lassere M, McGonagle D, McQueen F, O’Connor P,
Peterfy C, Schnier R, Stewart N, Ostergaard M: Magnetic reso-
nance imaging in rheumatoid arthritis: summary of OMERACT
activities, current status, and plans. J Rheumatol 2001,  28:
1158-1162.